Claritromicina EG (Clarithromycin) is a specialized antibiotic applied across therapeutic domains where additional symptomatic support is needed, focusing on conditions driven by susceptible bacteria and the subsequent symptomatic distress. It is commonly used to help manage conditions presenting with systemic or localized discomfort due to bacterial infections.

The medication is relevant in clinical settings that involve acute or unstable symptom patterns, such as those seen in pneumonia, acute bronchitis, sinusitis, cellulitis, acute otitis media, and as a part of combination therapy to address the infectious cause of duodenal ulcers (H. pylori bacterium).

“The medication is applied across domains where additional symptomatic support is needed when symptoms related to bacterial activity become more noticeable, which assists with maintaining functional stability.”

This treatment is commonly used to help address symptom clusters that may become intense or disruptive, including fever, persistent cough, and localized inflammatory pain. Furthermore, it is considered relevant in contexts involving heightened systemic burden, such as when an individual has a penicillin allergy, or is applied in addressing conditions involving inflammatory or irritative processes, such as Disseminated Mycobacterium Avium Complex (MAC). It provides support that helps ease the overall symptom burden and contributes to improved day-to-day comfort.

Quick Fact: Relief for Key Symptom Domains
Primary Focus	Conditions involving inflammatory or irritative states due to susceptible bacteria.
Symptom Benefit	Helps address fever, localized pain, cough, and symptoms that create noticeable physiological strain.
Context of Use	Applied when short-term symptomatic assistance is needed during acute episodes.
Patient Benefit	Supports patients during difficult episodes by easing distress and maintaining functional stability.

Regulatory References

1. NIH MedlinePlus Drug Information on Clarithromycin

Official Population Eligibility for Clarithromycin

Official regulatory documents define strict criteria for who can and cannot use Claritromicina EG (Clarithromycin).

Category	Official Regulatory Classification (Summary)
Populations for whom use is allowed	Adults and adolescents (typically 12 years and older). Children from six months to 12 years (generally via oral suspension).
Populations for whom use is contraindicated	Patients with known hypersensitivity to any macrolide antibiotic. Individuals with a history of QT prolongation or ventricular cardiac arrhythmia (including Torsades de Pointes). Patients with severe hepatic failure combined with renal impairment. Those with uncorrected hypokalaemia (low potassium) [Source: EMA/FDA].
Age-related restrictions	Use is not established or not recommended in infants younger than six months of age. Film-coated tablets are not recommended for children under 12 years of age [Source: EMA].
Conditional restrictions	Use is restricted for patients with severe renal impairment (creatinine clearance < 30 mL/min) and requires a reduced dosage [Source: FDA]. Caution is required in patients with pre-existing conditions like coronary artery disease or Myasthenia Gravis [Source: FDA].
Pregnancy/Lactation status	Use is not recommended during pregnancy, especially the first trimester, unless no alternative is appropriate. Use is not recommended during breastfeeding [Source: EMA/Health Canada].

Connection to the overall eligibility profile:

Regulatory documents define patient eligibility through a list of absolute contraindications related to cardiac history, macrolide allergy, and combined severe organ failure. The profile establishes conditional non-eligibility for infants, pregnant women, and breastfeeding patients, while mandating specific dose adjustments for those with severe kidney dysfunction.

The official interaction profile of Claritromicina EG (Clarithromycin) is defined by its regulatory classification as a strong inhibitor of the CYP3A4 enzyme and the P-glycoprotein transporter. This modulation of metabolic pathways causes a significant increase in the systemic exposure of numerous co-administered medicinal products.

Formal Contraindicated Combinations

Co-administration with the following medicines is strictly prohibited by regulatory authorities due to the high risk of severe, life-threatening outcomes:

• Astemizole, Cisapride, Pimozide, Terfenadine, Domperidone: Prohibited due to the risk of QT prolongation and serious cardiac arrhythmias.
• Ergot Alkaloids (Ergotamine, Dihydroergotamine): Prohibited due to the risk of acute ergot toxicity, including vasospasm.
• HMG-CoA Reductase Inhibitors (Statins): Lovastatin and Simvastatin are prohibited due to the risk of myopathy and rhabdomyolysis from markedly increased exposure.
• Other Agents: Lomitapide, Lurasidone, Ticagrelor, Ranolazine, Ivabradine, and Oral Midazolam are also formally contraindicated.

Population and Timing Restrictions

The interaction with Colchicine is contraindicated in patients with concurrent renal or hepatic impairment. Clarithromycin is also prohibited in patients with pre-existing hypokalaemia or hypomagnesaemia due to the associated risk of QT prolongation. The extended-release tablet formulation carries the administration constraint that it must be taken with food.

Targeted Inhibition of Bacterial Protein Synthesis

Claritromicina EG is an antimicrobial agent that works by directly targeting the 50S ribosomal subunit within susceptible bacteria. By binding specifically to the 23S ribosomal RNA, the agent actively blocks the translocation step required for protein chain elongation. This mechanistic cascade immediately prevents the synthesis of essential structural and enzymatic proteins necessary for cellular processes and division.

---

Selective Antimicrobial Action

The mechanism exhibits high mechanistic selectivity because the prokaryotic 50S ribosomal subunit is structurally distinct from the ribosomes found in human host cells. This targeted interference with the bacterial translational machinery leads to a bacteriostatic effect, which limits the ability of the target microbial cells to multiply and grow. This action assists in reducing the overall bacterial population density, contributing to a controlled environment within the targeted pathways.

Claritromicina EG (Clarithromycin) is officially administered via the oral route using immediate-release (IR) tablets, extended-release (ER) tablets, or oral suspension, and the intravenous (IV) route for acutely ill patients. The IV administration is designed to be a short course, generally two to five days, before switching to oral therapy; the total duration for typical courses is most often 7 to 14 days.

---

Standard Regimens and Frequency

The standard pattern for IR forms involves a dose ranging from 250 mg to 500 mg, taken twice daily (every 12 hours). The ER form is generally dosed at 1 gram and administered once daily. Children under 12 years are usually administered the oral suspension, which utilizes a weight-based dosing calculation, typically divided every 12 hours.

---

Specific Administration Requirements

A key administration difference is the relationship to meals: IR forms may be taken with or without food, whereas the ER tablets must be taken with food to achieve optimal absorption. The ER tablets must be swallowed whole and are not designed to be crushed or chewed. Furthermore, the powder for infusion must be diluted appropriately and administered over a period of 60 minutes. Officially labeled instructions also mandate a dose reduction by one-half for individuals diagnosed with severe renal impairment.

Research evidence / Overview of studies for Claritromicina EG

This section summarizes the structure of the clinical research that has evaluated Clarithromycin, the active ingredient in Claritromicina EG, based on data published by regulatory bodies and peer-reviewed scientific literature. This information outlines what is known about the evidence base and what areas remain uncertain; it is not intended to provide personal medical advice.

---

Evidence for Use in Acute Respiratory Tract Infections

This section summarizes the research base, including Randomized Controlled Trials (RCTs), that have evaluated the active ingredient Clarithromycin in research contexts involving infections of the lower airways (like pneumonia and acute bronchitis) and the upper airways (such as sinusitis and otitis media). The text will describe the types of clinical outcomes measured by researchers in these studies, such as symptom resolution and clinical improvement.

Research scenarios involved studies conducted during periods of increased symptom activity in patients with conditions associated with acute or disruptive episodes affecting the lungs and upper airways. The evidence base for the primary indications is extensive, largely derived from consistent Randomized Controlled Trials, though results apply only to the specific populations studied. A key area of research uncertainty involves assessing the impact of rising bacterial resistance to Clarithromycin in common pathogens.

---

Evidence for Eradication of H. pylori

This part outlines the clinical trials, including meta-analyses, that examined the role of this antibiotic as a component within multi-drug therapy regimens for conditions where the bacterium Helicobacter pylori is present, as associated with duodenal ulcers. It will describe how researchers measured success rates and tracked patients following treatment completion.

Clarithromycin was evaluated as a component within multi-drug regimens, which often included two or three other medicines, for conditions where the bacterium was present. Data show patterns related to the reported eradication rates across various multi-drug combinations and durations. The evidence highlights that rising global resistance is a key research limitation noted in the research. Certainty remains low that the same outcomes will be achieved in all areas.

---

Studies Involving Children and Specific Patient Groups

This section summarizes what research has specifically focused on outcomes and study designs for children (using the suspension formulation) and other defined subgroups, detailing the unique populations included in the clinical evidence base. The suspension formulation was evaluated in research contexts involving infections in the paediatric population, and studies explored symptom intensity or variability in acute conditions such as otitis media. Results apply only to the populations studied, and data for certain groups (such as pregnant or breastfeeding populations) remain insufficient or limited.

Key Studies & References Clarithromycin Drug Information: MedlinePlus

Common questions about Claritromicina EG (FAQ)

Q: What kind of infections is Claritromicina EG typically used for?

A: According to official regulatory documents, this antibiotic is indicated for treating a range of mild-to-moderate bacterial infections. This typically includes infections of the upper and lower respiratory tract, such as certain types of pneumonia and pharyngitis, as well as uncomplicated skin infections. It is also used as a component in treatment regimens aimed at eradicating the H. pylori bacteria.

Q: Is there a different name for Claritromicina EG?

A: Claritromicina EG contains the active ingredient Clarithromycin. Clarithromycin is the name used across all official regulatory sources to describe the core chemical compound, and it is available under various generic and brand names globally.

Q: Are there any common foods or drinks that interact with Claritromicina EG?

A: Official guidance for the Extended-Release formulation requires it to be taken with food for proper absorption. Regarding certain fruit juices, such as grapefruit juice, studies indicate they may affect how the antibiotic is metabolized by the body. This is due to the juice potentially inhibiting the CYP3A4 enzyme, which could alter the drug’s concentration.

Q: Can people with liver problems use Claritromicina EG?

A: Official documents indicate that use is contraindicated in patients with severe hepatic failure combined with renal impairment. For individuals with other forms of impaired hepatic function, caution and monitoring are necessary, and treatment should be discontinued if signs of liver problems develop.

Q: Why is Claritromicina EG prescribed for H. pylori infections?

A: Official product information describes its use as an essential component of a multi-drug regimen. This triple therapy approach is utilized to eradicate the H. pylori bacteria in patients with duodenal ulcer disease, which is critical for reducing the risk of ulcer recurrence.

Q: What does the patient leaflet mean by 'prolonged QT interval'?

A: Official warnings describe QT prolongation as a change in the heart’s electrical activity. This change is associated with an increased risk of developing a serious, life-threatening type of irregular heart rhythm (arrhythmia), such as torsades de pointes.

Q: Is Claritromicina EG effective against viruses?

A: No. This medication is officially classified as a macrolide antibiotic, which works only by inhibiting the growth and spread of bacteria. Official information confirms that antibiotics are not effective against infections caused by viruses, such as the common cold or flu.

Q: Can Claritromicina EG cause allergic reactions?

A: Yes, official safety information indicates that the drug can cause serious allergic reactions. These reactions may include hives, rash, severe itching, and swelling of the face or throat. It is also associated with severe skin reactions like Stevens-Johnson Syndrome.

Q: Is Claritromicina EG used for dental infections?

A: Official indications for Clarithromycin include the treatment of certain odontogenic infections. These are bacterial infections that originate in the teeth or surrounding oral structures.

Q: Is it normal to feel dizzy or lightheaded after taking Claritromicina EG?

A: According to official safety information, dizziness and headache are listed among the common side effects of the medication. The product information also reports that the medicine may sometimes cause patients to feel confused or disoriented.

Q: Can I take Claritromicina EG if I'm on birth control pills?

A: Official drug interaction data indicates that Clarithromycin is generally not thought to reduce the effectiveness of hormonal contraceptives. However, if a patient experiences vomiting or severe diarrhea for a prolonged period, the absorption and effectiveness of the contraceptive may be reduced.

Q: Does Claritromicina EG interact with blood thinners?

A: Yes, regulatory documents confirm a significant interaction risk. Taking the drug with blood thinners such as warfarin may cause a person to bleed more easily. This combination requires careful management and frequent monitoring of blood clotting levels (INR).

Q: Can older adults generally use Claritromicina EG?

A: Official geriatric use information advises caution for older adults due to a higher frequency of impaired organ function. Use in the geriatric population is specifically associated with an increased risk of a serious, irregular heartbeat called torsades de pointes.

Q: Is there a risk of tendon damage with Claritromicina EG?

A: Official adverse reaction lists for Clarithromycin do not list tendon rupture or damage as a reported common or serious side effect. This type of reaction is typically associated with a different class of antibiotics.

Q: What should I do if I miss a dose of Claritromicina EG?

A: Official administration instructions address missed doses. Patients should follow the specific guidance provided in the patient information leaflet or by a qualified healthcare provider regarding when to take a missed dose and when to skip it.

Q: How long does Claritromicina EG stay in your system after you stop taking it?

A: Pharmacokinetic data from official documents shows that the elimination half-life of Clarithromycin is approximately 3 to 7 hours, depending on the specific dose taken. Based on this, the drug is typically eliminated from the body within a few days after the last dose.

Q: Is Claritromicina EG related to penicillin?

A: No. Claritromicina EG is formally classified as a macrolide antibiotic, which is a chemical class distinct from penicillin. Official documents indicate that it may be used as an alternative agent in certain infections when penicillin is not appropriate.

Q: Can Claritromicina EG cause yeast infections?

A: Official safety information indicates that the drug may cause unusual vaginal discharge, itching, or odor. These symptoms can be related to a secondary infection, often called a superinfection, such as a yeast infection.

Q: Why is it important to complete the full course of Claritromicina EG?

A: Official regulatory warnings emphasize the importance of completing the full course of treatment. This practice helps to reduce the development of drug-resistant bacteria and ensures that the initial infection is fully resolved.

Q: Does Claritromicina EG cause anxiety or mood changes?

A: Official reports of adverse reactions include the transient central nervous system effects of anxiety, confusion, disorientation, hallucinations, and psychosis. These are listed as side effects that have been reported with this drug.

Q: What happens if Claritromicina EG is taken with alcohol?

A: Official information does not typically report a direct, negative interaction between alcohol consumption and the antibiotic's effectiveness. Therefore, consuming alcohol does not typically reduce the antibiotic's effectiveness.

Q: Can Claritromicina EG cause changes in vision?

A: Yes, official safety reports indicate that in rare cases, visual disturbances have been reported. These side effects include instances of double vision and blurred vision.

Q: Is it safe to drive while taking Claritromicina EG?

A: Official warnings state that while the drug is not expected to affect driving ability directly, certain side effects may interfere. Official warnings indicate that due to the potential for side effects such as dizziness, confusion, or vertigo, activities like driving or operating machinery may be impaired.

Q: Why is grapefruit juice mentioned in relation to Claritromicina EG?

A: Grapefruit juice is often mentioned because it can inhibit the CYP3A4 enzyme in the body. Since this enzyme is responsible for metabolizing the antibiotic, inhibiting it can potentially alter the drug's concentration in the blood, which is documented in drug interaction studies.

Official Storage and Disposal Requirements

The storage and disposal instructions for Clarithromycin (Claritromicina EG) are strictly defined by regulatory authorities to ensure safety and stability.

Requirement	Official Statement Summary
Storage Temperature	Store tablets at controlled room temperature, typically 20 C to 25 C.
Environmental Protection	Keep the medicine in its original, tightly closed container and protect from light and moisture.
Prohibited Conditions	Do not freeze either the tablets or the oral suspension. The reconstituted suspension should not be refrigerated.
Stability (Liquid)	The reconstituted oral suspension must be used or safely discarded within 14 days of preparation.
Child Safety	Keep the medication and all other medicines out of the reach of children.
Disposal	Safely dispose of any unused or expired medicine according to local regulatory requirements. Do not flush down a toilet or pour down a drain.